Immunohistochemical ETS-related gene detection in a Japanese prostate cancer cohort: Diagnostic use in Japanese prostate cancer patients

Pathology International

Volumn 61, Issue 7, 2011, Pages 409-414

  Furusato, Bungo ^a,c   van Leenders, Geert J H L ^d   Trapman, Jan ^d   Kimura, Takahiro ^b   Egawa, Shin ^b   Takahashi, Hiroyuki ^a   Furusato, Masakuni ^a,c   Visakorpi, Tapio ^e   Hano, Hiroshi ^a  

^a Departments of Pathology   (Japan)

^b JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c International Pathology Laboratory Company Ltd   (Japan)

^d JOSEPHINE NEFKENS INSTITUTE   (Netherlands)

^e UNIVERSITY OF TAMPERE   (Finland)

Author keywords

Asian; ERG; Immunohistochemistry; Japanese; Prostate cancer; Race

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; TRANSCRIPTION FACTOR ERG;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER GRADING; CANCER STAGING; CHROMOSOME REARRANGEMENT; CORRELATION ANALYSIS; DIAGNOSTIC TEST ACCURACY STUDY; GENE; GENE IDENTIFICATION; GENE OVEREXPRESSION; HUMAN; JAPANESE; MAJOR CLINICAL STUDY; MALE; METASTASIS; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; SENSITIVITY AND SPECIFICITY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; COHORT STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; JAPAN; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSTATIC NEOPLASMS; TRANS-ACTIVATORS; TUMOR MARKERS, BIOLOGICAL;

EID: 79959637195     PISSN: 13205463     EISSN: 14401827     Source Type: Journal    
DOI: 10.1111/j.1440-1827.2011.02675.x     Document Type: Article

References (59)

1. Mostofi FK, Davis CJ Jr, Sesterhenn IA. Pathology of carcinoma of the prostate. Cancer 1992; 70: 235-53.
2. Epstein JI. Diagnosis and reporting of limited adenocarcinoma of the prostate on needle biopsy. Mod Pathol 2004; 17: 307-15.
3. Humphrey PA. Diagnosis of adenocarcinoma in prostate needle biopsy tissue. J Clin Pathol 2007; 60: 35-42.
4. Browne TJ, Hirsch MS, Brodsky G, Welch WR, Loda MF, Rubin MA. Prospective evaluation of AMACR (P504S) and basal cell markers in the assessment of routine prostate needle biopsy specimens. Hum Pathol 2004; 35: 1462-8.
5. Rubin MA, Zhou M, Dhanasekaran SM etal. alpha-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer. JAMA 2002; 287: 1662-70.
6. Kuefer R, Varambally S, Zhou M etal. alpha-Methylacyl-CoA racemase: Expression levels of this novel cancer biomarker depend on tumor differentiation. Am J Pathol 2002; 161: 841-8.
7. Zhou M, Chinnaiyan AM, Kleer CG, Lucas PC, Rubin MA. Alpha-Methylacyl-CoA racemase: A novel tumor marker over-expressed in several human cancers and their precursor lesions. Am J Surg Pathol 2002; 26: 926-31.
8. Attard G, Clark J, Ambroisine L etal. Heterogeneity and clinical significance of ETV1 translocations in human prostate cancer. Br J Cancer 2008; 99: 314-20.
9. Helgeson BE, Tomlins SA, Shah N etal. Characterization of TMPRSS2:ETV5 and SLC45A3:ETV5 gene fusions in prostate cancer. Cancer Res 2008; 68: 73-80.
10. Hermans KG, Bressers AA, van der Korput HA, Dits NF, Jenster G, Trapman J. Two unique novel prostate-specific and androgen-regulated fusion partners of ETV4 in prostate cancer. Cancer Res 2008; 68: 3094-8.
11. Tomlins SA, Mehra R, Rhodes DR etal. TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer. Cancer Res 2006; 66: 3396-400.
12. Tomlins SA, Laxman B, Dhanasekaran SM etal. Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature 2007; 448: 595-9.
13. Tomlins SA, Rhodes DR, Perner S etal. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005; 310: 644-8.
14. Miyagi Y, Sasaki T, Fujinami K etal. ETS family-associated gene fusions in Japanese prostate cancer: Analysis of 194 radical prostatectomy samples. Mod Pathol 2010; 23: 1492-8.
15. Magi-Galluzzi C, Tsusuki T, Elson P etal. TMPRSS2-ERG gene fusion prevalence and class are significantly different in prostate cancer of caucasian, african-american and japanese patients. Prostate 2011; 71: 489-97.
16. Park K, Tomlins SA, Mudaliar KM etal. Antibody-based detection of ERG rearrangement-positive prostate cancer. Neoplasia 2010; 12: 590-98.
17. Epstein JI, Allsbrook WC Jr, Amin MB, Egevad LL. The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol 2005; 29: 1228-42.
18. Egevad L, Srigley JR, Delahunt B. International Society of Urological Pathology (ISUP) consensus conference on handling and staging of radical prostatectomy specimens: Rationale and organization. Mod Pathol 2011; 24: 1-5.
19. Samaratunga H, Montironi R, True L etal. International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 1: Specimen handling. Mod Pathol 2011; 24: 6-15.
20. van der Kwast TH, Amin MB, Billis A etal. International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 2: T2 substaging and prostate cancer volume. Mod Pathol 2011; 24: 16-25.
21. Magi-Galluzzi C, Evans AJ, Delahunt B etal. International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 3: Extraprostatic extension, lymphovascular invasion and locally advanced disease. Mod Pathol 2011; 24: 26-38.
22. Berney DM, Wheeler TM, Grignon DJ etal. International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 4: Seminal vesicles and lymph nodes. Mod Pathol 2011; 24: 39-47.
23. Tan PH, Cheng L, Srigley JR etal. International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 5: Surgical margins. Mod Pathol 2011; 24: 48-57.
24. Furusato B, Tan SH, Young D etal. ERG oncoprotein expression in prostate cancer: Clonal progression of ERG-positive tumor cells and potential for ERG-based stratification. Prostate Cancer Prostatic Dis 2010; 13: 228-37.
25. Iwamoto M, Tamamura Y, Koyama E etal. Transcription factor ERG and joint and articular cartilage formation during mouse limb and spine skeletogenesis. Dev Biol 2007; 305: 40-51.
26. Birdsey GM, Dryden NH, Amsellem V etal. Transcription factor Erg regulates angiogenesis and endothelial apoptosis through VE-cadherin. Blood 2008; 111: 3498-506.
27. Yang L, Xia L, Wu DY etal. Molecular cloning of ESET, a novel histone H3-specific methyltransferase that interacts with ERG transcription factor. Oncogene 2002; 21: 148-52.
28. Petrovics G, Liu A, Shaheduzzaman S etal. Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome. Oncogene 2005; 24: 3847-52.
29. Scheble VJ, Braun M, Beroukhim R etal. ERG rearrangement is specific to prostate cancer and does not occur in any other common tumor. Mod Pathol 2010; 23: 1061-7.
30. Leinonen KA, Tolonen TT, Bracken H etal. Association of SPINK1 expression and TMPRSS2:ERG fusion with prognosis in endocrine-treated prostate cancer. Clin Cancer Res 2010; 16: 2845-51.
31. Fine SW, Gopalan A, Leversha MA etal. TMPRSS2-ERG gene fusion is associated with low Gleason scores and not with high-grade morphological features. Mod Pathol 2010; 23: 1325-33.
32. Rostad K, Hellwinkel OJ, Haukaas SA etal. TMPRSS2:ERG fusion transcripts in urine from prostate cancer patients correlate with a less favorable prognosis. APMIS 2009; 117: 575-82.
33. Mosquera JM, Mehra R, Regan MM etal. Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States. Clin Cancer Res 2009; 15: 4706-11.
34. Lu B, Maqsodi B, Yang W etal. Detection of TMPRSS2-ERG fusion gene expression in prostate cancer specimens by a novel assay using branched DNA. Urology 2009; 74: 1156-61.
35. Hermans KG, Boormans JL, Gasi D etal. Overexpression of prostate-specific TMPRSS2(exon 0)-ERG fusion transcripts corresponds with favorable prognosis of prostate cancer. Clin Cancer Res 2009; 15: 6398-403.
36. Furusato B, Gao CL, Ravindranath L etal. Mapping of TMPRSS2-ERG fusions in the context of multi-focal prostate cancer. Mod Pathol 2008; 21: 67-75.
37. Rajput AB, Miller MA, De Luca A etal. Frequency of the TMPRSS2:ERG gene fusion is increased in moderate to poorly differentiated prostate cancers. J Clin Pathol 2007; 60: 1238-43.
38. Nam RK, Sugar L, Wang Z etal. Expression of TMPRSS2:ERG gene fusion in prostate cancer cells is an important prognostic factor for cancer progression. Cancer Biol Ther 2007; 6: 40-45.
39. Mehra R, Han B, Tomlins SA etal. Heterogeneity of TMPRSS2 gene rearrangements in multifocal prostate adenocarcinoma: Molecular evidence for an independent group of diseases. Cancer Res 2007; 67: 7991-5.
40. Ito K, Kakehi Y, Naito S, Okuyama A. Japanese Urological Association guidelines on prostate-specific antigen-based screening for prostate cancer and the ongoing cluster cohort study in Japan. Int J Urol 2008; 15: 763-8.
41. Guo CC, Zuo G, Cao D, Troncoso P, Czerniak BA. Prostate cancer of transition zone origin lacks TMPRSS2-ERG gene fusion. Mod Pathol 2009; 22: 866-71.
42. Clark J, Attard G, Jhavar S etal. Complex patterns of ETS gene alteration arise during cancer development in the human prostate. Oncogene 2008; 27: 1993-2003.
43. Falzarano SM, Navas M, Simmerman K etal. ERG rearrangement is present in a subset of transition zone prostatic tumors. Mod Pathol 2010; 23: 1499-506.
44. Perner S, Mosquera JM, Demichelis F etal. TMPRSS2-ERG fusion prostate cancer: An early molecular event associated with invasion. Am J Surg Pathol 2007; 31: 882-8.
45. Attard G, Clark J, Ambroisine L etal. Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer. Oncogene 2008; 27: 253-63.
46. Cheville JC, Karnes RJ, Therneau TM etal. Gene panel model predictive of outcome in men at high-risk of systemic progression and death from prostate cancer after radical retropubic prostatectomy. J Clin Oncol 2008; 26: 3930-36.
47. Demichelis F, Fall K, Perner S etal. TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene 2007; 26: 4596-9.
48. Nam RK, Sugar L, Yang W etal. Expression of the TMPRSS2:ERG fusion gene predicts cancer recurrence after surgery for localised prostate cancer. Br J Cancer 2007; 97: 1690-95.
49. Saramaki OR, Harjula AE, Martikainen PM, Vessella RL, Tammela TL, Visakorpi T. TMPRSS2:ERG fusion identifies a subgroup of prostate cancers with a favorable prognosis. Clin Cancer Res 2008; 14: 3395-400.
50. Gopalan A, Leversha MA, Satagopan JM etal. TMPRSS2-ERG gene fusion is not associated with outcome in patients treated by prostatectomy. Cancer Res 2009; 69: 1400-6.
51. Rouzier C, Haudebourg J, Carpentier X etal. Detection of the TMPRSS2-ETS fusion gene in prostate carcinomas: Retrospective analysis of 55 formalin-fixed and paraffin-embedded samples with clinical data. Cancer Genet Cytogenet 2008; 183: 21-7.
52. Winnes M, Lissbrant E, Damber JE, Stenman G. Molecular genetic analyses of the TMPRSS2-ERG and TMPRSS2-ETV1 gene fusions in 50 cases of prostate cancer. Oncol Rep 2007; 17: 1033-6.
53. Darnel AD, Lafargue CJ, Vollmer RT, Corcos J, Bismar TA. TMPRSS2-ERG fusion is frequently observed in Gleason pattern 3 prostate cancer in a Canadian cohort. Cancer Biol Ther 2009; 8: 125-30.
54. Perner S, Demichelis F, Beroukhim R etal. TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res 2006; 66: 8337-41.
55. Mehra R, Tomlins SA, Shen R etal. Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer. Mod Pathol 2007; 20: 538-44.
56. Villers A, McNeal JE, Freiha FS, Stamey TA. Multiple cancers in the prostate. Morphologic features of clinically recognized versus incidental tumors. Cancer 1992; 70: 2313-8.
57. Djavan B, Susani M, Bursa B, Basharkhah A, Simak R, Marberger M. Predictability and significance of multifocal prostate cancer in the radical prostatectomy specimen. Tech Urol 1999; 5: 139-42.
58. Bostwick DG, Shan A, Qian J etal. Independent origin of multiple foci of prostatic intraepithelial neoplasia: Comparison with matched foci of prostate carcinoma. Cancer 1998; 83: 1995-2002.
59. Gavrilov D, Kenzior O, Evans M, Calaluce R, Folk WR. Expression of urokinase plasminogen activator and receptor in conjunction with the ets family and AP-1 complex transcription factors in high grade prostate cancers. Eur J Cancer 2001; 37: 1033-40.